Q1 2025 Vaxart Inc Earnings Call Transcript

May 13, 2025 / 08:30 PM GMT

Release Date Price: €0.3448 (-4.06%)

Transcript 10-Q8-K

Key Points

Positve

Vaxart Inc (VXRT) successfully lifted the stop work order on their 10,000 participant COVID-19 Phase 2B vaccine trial, indicating progress in their clinical development.
The company completed enrollment in their Phase 1 norovirus vaccine trial, showing efficiency in advancing their clinical programs.
Vaxart Inc (VXRT) reported a significant increase in revenue for Q1 2025, primarily due to their BARDA contract, indicating strong financial performance.
The company is actively pursuing strategic partnerships, which could provide non-dilutive funding and further advance their vaccine programs.
Vaxart Inc (VXRT) has a new CFO, Jerome Grossman, who brings over 20 years of experience in biotech, potentially strengthening their financial leadership.

Negative

Vaxart Inc (VXRT) faced a stop work order on their COVID-19 trial, which caused delays in their clinical timeline.
The company had to implement workforce reductions to manage costs, indicating financial constraints.
Vaxart Inc (VXRT) is at risk of being delisted from NASDAQ due to not meeting the $1 minimum bid price requirement, which could impact their stock liquidity and investor interest.
The resignation of their CFO, Phil Lee, for personal reasons, may cause transitional challenges in their financial management.
The company is considering a reverse stock split as a last resort to maintain NASDAQ listing, which could affect shareholder value.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VXRT.OQ - Vaxart Inc
Q1 2025 Vaxart Inc Earnings Call
May 13, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings. Welcome to Vacart Business Update and first quarter 2025 financial results conference call. A question and answer session will follow management's opening remarks. Individual investors may submit written questions to IR at vaxar.com. As a reminder, this conference is being recorded. I would now like to turn the webcast over to your host Ed Berg, senior Vice President and general counsel.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon and welcome to today's call.

Joining us from Vacart are Stephen Lowe, Chief Executive Officer, Doctor Sean Tucker, founder and Chief

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.